Publication date: October 2026 Source: The Lancet Infectious Diseases, Volume 26, Issue 10 Author(s): Frank Bähner, Saul N Faust, Leela R L Davies, Olga Blokhina, Donald M Brandon, William B Smith, Vengalil Krishna K Chatterjee, Hana Hassanin, Tara M Babu, Adam Zuiani, Susanne Steinhauser, Asaf Poran, Claire Brittain, Eric Mucker, Jay W Hooper, Robbert G van der Most, Pedro L Alonso, Özlem Türeci, Federico J Mensa, Uğur Şahin
Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial. // The Lancet Infectious Diseases. – URL: https://www.sciencedirect.com/science/article/pii/S1473309926001775?dgcid=rss_sd_all
Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial. The Lancet Infectious Diseases. https://www.sciencedirect.com/science/article/pii/S1473309926001775?dgcid=rss_sd_all
“Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial.” The Lancet Infectious Diseases.
@article{article108826,
title = {Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial},
journal = {The Lancet Infectious Diseases},
url = {https://www.sciencedirect.com/science/article/pii/S1473309926001775?dgcid=rss_sd_all}
}
ABSTRACT Background Aspergillus fumigatus can cause life‐threatening infections, primarily treated with azole antifungals. Azole‐resistant A. fumigatus (ARAF) is a major clinical concern. Environmental resistance development is an...
ABSTRACT Background The lipid‐dependent yeast genus Malassezia is composed of skin commensals that can become pathogenic. This genus can cause bloodstream infection in low‐weight preterm neonates and immunocompromised adults. However,...